Therapeutic interventions in sepsis: Current and anticipated pharmacological agents

British Journal of Pharmacology

Volumn 171, Issue 22, 2014, Pages 5011-5031

  Shukla, Prashant ^a   Rao, G Madhava ^a   Pandey, Gitu ^a   Sharma, Shweta ^a   Mittapelly, Naresh ^a   Shegokar, Ranjita ^b   Mishra, Prabhat Ranjan ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ALT 836; ANTIINFECTIVE AGENT; ATORVASTATIN; BICIZAR; CATHELICIDIN; CITRULLINE; COMPLEMENT COMPONENT C5A RECEPTOR; CYTOFAB; DROTRECOGIN; ERITORAN; ESTROGEN RECEPTOR BETA; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1BETA; INTERLEUKIN 8; INTRALIPID; LACTOFERRIN; LACTOFERRIN ALPHA; MESOPARAN; PEPTIDE DERIVATIVE; PEPTOID 7; POLYMYXIN B; RECOMBINANT THROMBOMODULIN; RESATORVID; SRT 2379; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; LIPOPOLYSACCHARIDE;

ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; CARDIOVASCULAR DISEASE; CELL ACTIVATION; CELL MIGRATION; CELL PROLIFERATION; CELL PROTECTION; CYTOKINE RELEASE; DRUG BINDING; DRUG EFFICACY; ENDOTHELIUM CELL; FIBRINOLYSIS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; KIDNEY INJURY; LIVER INJURY; LUNG INJURY; MACROPHAGE; MESENCHYMAL STEM CELL; METABOLOMICS; MICROANGIOPATHY; MORTALITY; NEUTROPHIL; NONHUMAN; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SEPSIS; SEPTIC SHOCK; STEM CELL; ANIMAL; CARDIOVASCULAR SYSTEM; IMMUNOLOGY; KIDNEY; LIVER; LUNG; METABOLISM;

ANIMALS; CARDIOVASCULAR SYSTEM; HUMANS; KIDNEY; LIPOPOLYSACCHARIDES; LIVER; LUNG; SEPSIS;

EID: 84915785108     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12829     Document Type: Review

References (161)

1. Abraham E, Singer M (2007). Mechanisms of sepsis-induced organ dysfunction. Crit Care Med 35: 2408-2416.
2. Ackland GL, Gutierrez Del Arroyo A, Yao ST, Stephens RC, Dyson A, Klein NJ et al. (2010). Low-molecular-weight polyethylene glycol improves survival in experimental sepsis. Crit Care Med 38: 629-636.
3. Albayrak A, Halici Z, Polat B, Karakus E, Cadirci E, Bayir Y et al. (2013). Protective effects of lithium: a new look at an old drug with potential antioxidative and anti-inflammatory effects in an animal model of sepsis. Int Immunopharmacol 16: 35-40.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
5. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
6. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Nuclear Hormone Receptors. Br J Pharmacol 170: 1652-1675.
7. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013d). The Concise Guide to PHARMACOLOGY 2013/14: Catalytic Receptors. Br J Pharmacol 170: 1676-1705
8. Almeida WS, Maciel TT, Di Marco GS, Casarini DE, Campos AH, Schor N (2006). Escherichia coli lipopolysaccharide inhibits renin activity in human mesangial cells. Kidney Int 69: 974-980.
9. Alves-Filho JC, Sonego F, Souto FO, Freitas A, Verri WA Jr, Auxiliadora-Martins M et al. (2010). Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat Med 16: 708-712.
10. Anas AA, Wiersinga WJ, de Vos AF, van der Poll T (2010). Recent insights into the pathogenesis of bacterial sepsis. Neth J Med 68: 147-152.
11. Andersson U, Tracey KJ (2003). HMGB1 in sepsis. Scand J Infect Dis 35: 577-584.
12. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR (2001). Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29: 1303-1310.
13. Bae EH, Kim IJ, Ma SK, Lee JU, Kim SW (2011). Altered regulation of renal nitric oxide and atrial natriuretic peptide systems in lipopolysaccharide-induced kidney injury. Korean J Physiol Pharmacol 15: 273-277.
14. Bajaj G, Van Alstine WG, Yeo Y (2012). Zwitterionic chitosan derivative, a new biocompatible pharmaceutical excipient, prevents endotoxin-mediated cytokine release. PLoS ONE 7: e30899.
15. Beffa DC, Fischman AJ, Fagan SP, Hamrahi VF, Paul KW, Kaneki M et al. (2011). Simvastatin treatment improves survival in a murine model of burn sepsis: role of interleukin 6. Burns 37: 222-226.
16. Benjamim CF, Lundy SK, Lukacs NW, Hogaboam CM, Kunkel SL (2005). Reversal of long-term sepsis-induced immunosuppression by dendritic cells. Blood 105: 3588-3595.
17. Bernard GR, Ely EW, Wright TJ, Fraiz J, Stasek JE Jr, Russell JA et al. (2001a). Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 29: 2051-2059.
18. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A et al. (2001b). Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699-709.
19. Beutler B (2002). TLR4 as the mammalian endotoxin sensor. Curr Top Microbiol Immunol 270: 109-120.
20. Boffa JJ, Arendshorst WJ (2005). Maintenance of renal vascular reactivity contributes to acute renal failure during endotoxemic shock. J Am Soc Nephrol 16: 117-124.
21. Brahmamdam P, Watanabe E, Unsinger J, Chang KC, Schierding W, Hoekzema AS et al. (2009). Targeted delivery of siRNA to cell death proteins in sepsis. Shock 32: 131-139.
22. Burns MR, Wood SJ, Miller KA, Nguyen T, Cromer JR, David SA (2005). Lysine-spermine conjugates: hydrophobic polyamine amides as potent lipopolysaccharide sequestrants. Bioorg Med Chem 13: 2523-2536.
23. Cai C, Hsieh CL, Gao S, Kannan A, Bhansali M, Govardhan K et al. (2012). Soluble guanylyl cyclase alpha1 and p53 cytoplasmic sequestration and down-regulation in prostate cancer. Mol Endocrinol 26: 292-307.
24. Calandra T, Roger T (2003). Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 3: 791-800.
25. Calisto KL, Camacho AC, Mittestainer FC, Carvalho BM, Guadagnini D, Carvalheira JB et al. (2012). Diacerhein attenuates the inflammatory response and improves survival in a model of severe sepsis. Critical care 16: R158.
26. Celes MRN, Prado CM, Rossi MA (2013). Sepsis: going to the heart of the matter. Pathobiology 80: 70-86.
27. Charchaflieh J, Wei J, Labaze G, Hou YJ, Babarsh B, Stutz H et al. (2012). The role of complement system in septic shock. Clin Dev Immunol 2012: 407324.
28. Chen G, Li J, Qiang X, Czura CJ, Ochani M, Ochani K et al. (2005). Suppression of HMGB1 release by stearoyl lysophosphatidylcholine: an additional mechanism for its therapeutic effects in experimental sepsis. J Lipid Res 46: 623-627.
29. Chen N, Liu D, Soromou LW, Sun J, Zhong W, Guo W et al. (2014). Paeonol suppresses lipopolysaccharide-induced inflammatory cytokines in macrophage cells and protects mice from lethal endotoxin shock. Fundam Clin Pharmacol 28: 268-276.
30. Chen RJ, Hongjie D (2003). Noncovalent functionalization of carbon nanotubes for highly specific electronic biosensors. Proc Natl Acad Sci USA 100: 4984-4989.
31. Cirioni O, Giacometti A, Ghiselli R, Bergnach C, Orlando F, Silvestri C et al. (2006). LL-37 protects rats against lethal sepsis caused by gram-negative bacteria. Antimicrob Agents Chemother 50: 1672-1679.
32. Comalada M, Camuesco D, Sierra S, Ballester I, Xaus J, Galvez J et al. (2005). In vivo quercitrin anti-inflammatory effect involves release of quercetin, which inhibits inflammation through down-regulation of the NF-kappaB pathway. Eur J Immunol 35: 584-592.
33. Crinelli R, Antonelli A, Bianchi M, Gentilini L, Scaramucci S, Magnani M (2000). Selective inhibition of NF-κB activation and TNF-α production in macrophages by red blood cell-mediated delivery of dexamethasone. Blood Cells Mol Dis 26: 211-222.
34. Cristofaro PA, Opal SM, Palardy JE, Parejo NA, Jhung J, Keith JC Jr et al. (2006). WAY-202196, a selective estrogen receptor-beta agonist, protects against death in experimental septic shock. Crit Care Med 34: 2188-2193.
35. Cvoro A, Tatomer D, Tee MK, Zogovic T, Harris HA, Leitman DC (2008). Selective estrogen receptor-beta agonists repress transcription of proinflammatory genes. J Immunol 180: 630-636.
36. Czermak BJ, Sarma V, Pierson CL, Warner RL, Huber-Lang M, Bless NM et al. (1999). Protective effects of C5a blockade in sepsis. Nat Med 5: 788-792.
37. David SA, Silverstein R, Amura CR, Kielian T, Morrison DC (1999). Lipopolyamines: novel antiendotoxin compounds that reduce mortality in experimental sepsis caused by gram-negative bacteria. Antimicrob Agents Chemother 43: 912-919.
38. Davies B, Cohen J (2011). Endotoxin removal devices for the treatment of sepsis and septic shock. Lancet Infect Dis 11: 65-71.
39. Dhainaut J-F, Marin N, Mignon A, Vinsonneau C (2001). Hepatic response to sepsis: interaction between coagulation and inflammatory processes. Crit Care Med 29: S42-S47.
40. Dhainaut JF, Yan SB, Claessens YE (2004). Protein C/activated protein C pathway: overview of clinical trial results in severe sepsis. Crit Care Med 32 (5 Suppl.): S194-S201.
41. Diao Y, Xin Y, Zhou Y, Li N, Pan X, Qi S et al. (2014). Extracellular polysaccharide from Bacillus sp. strain LBP32 prevents LPS-induced inflammation in RAW 264.7 macrophages by inhibiting NF-κB and MAPKs activation and ROS production. Int Immunopharmacol 18: 12-19.
42. Dobesh PP, Klepser DG, McGuire TR, Morgan CW, Olsen KM (2009). Reduction in mortality associated with statin therapy in patients with severe sepsis. Pharmacotherapy 29: 621-630.
43. Dolgin E (2012). Trial failure prompts soul-searching for critical-care specialists. Nat Med 18: 1000.
44. Donnahoo KK, Meng X, Ayala A, Cain MP, Harken AH, Meldrum DR (1999). Early kidney TNF-alpha expression mediates neutrophil infiltration and injury after renal ischemia-reperfusion. Am J Physiol 277 (3 Pt 2): R922-R929.
45. Dyson A, Singer M (2009). Animal models of sepsis: why does preclinical efficacy fail to translate to the clinical setting? Crit Care Med 37: S30-S37.
46. Elass E, Masson M, Mazurier J, Legrand D (2002). Lactoferrin inhibits the lipopolysaccharide-induced expression and proteoglycan-binding ability of interleukin-8 in human endothelial cells. Infect Immun 70: 1860-1866.
47. Falagas ME, Makris GC, Matthaiou DK, Rafailidis PI (2008). Statins for infection and sepsis: a systematic review of the clinical evidence. J Antimicrob Chemother 61: 774-785.
48. Farnaud S, Evans RW (2003). Lactoferrin - a multifunctional protein with antimicrobial properties. Mol Immunol 40: 395-405.
49. Feingold KR, Grunfeld C (2011). The role of HDL in innate immunity. J Lipid Res 52: 1-3.
50. Fodale V, Santamaria LB (2008). Cholinesterase inhibitors improve survival in experimental sepsis: a new way to activate the cholinergic anti-inflammatory pathway. Crit Care Med 36: 622-623.
51. Fraunberger P, Grone E, Grone HJ, Walli AK (2009). Simvastatin reduces endotoxin-induced nuclear factor kappaB activation and mortality in guinea pigs despite lowering circulating low-density lipoprotein cholesterol. Shock 32: 159-163.
52. Fry DE (1996). The importance of antibiotic pharmacokinetics in critical illness. Am J Surg 172: 20s-25s.
53. Fujimoto J, Wiener-Kronish JP, Hashimoto S, Sawa T (2002). Effects of CL2MDP-encapsulating liposomes in a murine model of Pseudomonas aeruginosa-induced sepsis. J Liposome Res 12: 239-257.
54. Giacometti A, Cirioni O, Ghiselli R, Bergnach C, Orlando F, D'Amato G et al. (2004). The antimicrobial peptide BMAP-28 reduces lethality in mouse models of staphylococcal sepsis. Crit Care Med 32: 2485-2490.
55. Giamarellos-Bourboulis EJ (2013). Failure of treatments based on the cytokine storm theory of sepsis: time for a novel approach. Immunotherapy 5: 207-209.
56. Gifford JL, Hunter HN, Vogel HJ (2005). Lactoferricin: a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. Cell Mol Life Sci 62: 2588-2598.
57. Goya T, Torisu M (1993). Potential role of hepatic macrophages in neutrophil-mediated liver injury in rats with sepsis. Hepatology 17: 1086-1094.
58. Gradisar H, Keber MM, Pristovsek P, Jerala R (2007). MD-2 as the target of curcumin in the inhibition of response to LPS. J Leukoc Biol 82: 968-974.
59. Greenlee KJ, Werb Z, Kheradmand F (2007). Matrix metalloproteinases in lung: multiple, multifarious, and multifaceted. Physiol Rev 87: 69-98.
60. Griffin JH, Fernandez JA, Gale AJ, Mosnier LO (2007). Activated protein C. J Thromb Haemost 5 (Suppl. 1): 73-80.
61. Guo W, Liu W, Chen G, Hong S, Qian C, Xie N et al. (2012). Water-soluble andrographolide sulfonate exerts anti-sepsis action in mice through down-regulating p38 MAPK, STAT3 and NF-kappaB pathways. Int Immunopharmacol 14: 613-619.
62. Hack CE, Zeerleder S (2001). The endothelium in sepsis: source of and a target for inflammation. Crit Care Med 29 (7 Suppl.): S21-S27.
63. Han YY, Huang L, Jackson EK, Dubey RK, Gillepsie DG, Carcillo JA (2001). Liposomal ATP or NAD+ protects human endothelial cells from energy failure in a cell culture model of sepsis. Res Commun Mol Pathol Pharmacol 110: 107-116.
64. Heeba GH, Mahmoud ME, El Hanafy AA (2014). Anti-inflammatory potential of curcumin and quercetin in rats: role of oxidative stress, heme oxygenase-1 and TNF-alpha. Toxicol Ind Health 30: 551-560.
65. Hirasawa H, Oda S, Nakamura M, Watanabe E, Shiga H, Matsuda K (2012). Continuous hemodiafiltration with a cytokine-adsorbing hemofilter for sepsis. Blood Purif 34: 164-170.
66. Hotchkiss RS, Monneret G, Payen D (2013). Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 13: 862-874.
67. Hotchkiss RS, Opal S (2010). Immunotherapy for sepsis - a new approach against an ancient foe. N Engl J Med 363: 87-89.
68. Huh AJ, Kwon YJ (2011). 'Nanoantibiotics': a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. J Control Release 156: 128-145.
69. Hultin M, Carneheim C, Rosenqvist K, Olivecrona T (1995). Intravenous lipid emulsions: removal mechanisms as compared to chylomicrons. J Lipid Res 36: 2174-2184.
70. Ince C (2005). The microcirculation is the motor of sepsis. Crit Care 9: S13-S19.
71. Izquierdo-Garcia JL, Nin N, Ruiz-Cabello J, Rojas Y, de Paula M, Lopez-Cuenca S et al. (2011). A metabolomic approach for diagnosis of experimental sepsis. Intensive Care Med 37: 2023-2032.
72. Jain V, Shukla P, Pal R, Mishra PR (2014). Cationic nanoemulsions bearing ciprofloxacin surf-plexes enhances its therapeutic efficacy in conditions of E. coli induced peritonitis and sepsis. Pharm Res. Available at: http://dx.doi.org/10.1007/s11095-014-1360-0 (accessed 26/07/2014).
73. Jiang Z, Hong Z, Guo W, Xiaoyun G, Gengfa L, Yongning L et al. (2004). A synthetic peptide derived from bactericidal/permeability-increasing protein neutralizes endotoxin in vitro and in vivo. Int Immunopharmacol 4: 527-537.
74. Kang G, Kong PJ, Yuh YJ, Lim SY, Yim SV, Chun W et al. (2004). Curcumin suppresses lipopolysaccharide-induced cyclooxygenase-2 expression by inhibiting activator protein 1 and nuclear factor kappaB bindings in BV2 microglial cells. J Pharmacol Sci 94: 325-328.
75. Kim J, Lee CM, Jeong HJ, Kim DW, Lee KY (2012). Elevated anti-inflammatory effects of eicosapentaenoic acid based self-aggregated glycol chitosan nanoparticles. J Nanosci Nanotechnol 12: 2672-2678.
76. Kim TH, Ku S-K, Bae J-S (2013a). Anti-inflammatory activities of isorhamnetin-3-O-galactoside against HMGB1-induced inflammatory responses in both HUVECs and CLP-induced septic mice. J Cell Biochem 114: 336-345.
77. Kim TH, Ku S-K, Bae J-S (2013b). Persicarin is anti-inflammatory mediator against HMGB1-induced inflammatory responses in HUVECs and in CLP-induced sepsis mice. J Cell Physiol 228: 696-703.
78. Krasnodembskaya A, Samarani G, Song Y, Zhuo H, Su X, Lee JW et al. (2012). Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Am J Physiol Lung Cell Mol Physiol 302: L1003-L1013.
79. Lee S (2001). Recognition properties of antibodies to PAMAM dendrimers and their use in immune detection of dendrimers. Biomed Microdevices 3: 53-59.
80. Lee S, Yang SC, Heffernan MJ, Taylor WR, Murthy N (2006). Polyketal microparticles: a new delivery vehicle for superoxide dismutase. Bioconjug Chem 18: 4-7.
81. Lee SC (2004). Biochemical and immunological properties of cytokines conjugated to dendritic polymers. Biomed Microdevices 6: 191-202.
82. Levy MM, Artigas A, Phillips GS, Rhodes A, Beale R, Osborn T et al. (2012). Outcomes of the Surviving Sepsis Campaign in intensive care units in the USA and Europe: a prospective cohort study. Lancet Infect Dis 12: 919-924.
83. Liu D, Yang PS (2012). Minocycline hydrochloride nanoliposomes inhibit the production of TNF-alpha in LPS-stimulated macrophages. Int J Nanomedicine 7: 4769-4775.
84. Liu JJ, Song CW, Yue Y, Duan CG, Yang J, He T et al. (2005). Quercetin inhibits LPS-induced delay in spontaneous apoptosis and activation of neutrophils. Inflamm Res 54: 500-507.
85. Liu X, Zheng X, Wang N, Cao H, Lu Y, Long Y et al. (2011a). Kukoamine B, a novel dual inhibitor of LPS and CpG DNA, is a potential candidate for sepsis treatment. Br J Pharmacol 162: 1274-1290.
86. Liu XR, Zheng XF, Ji SZ, Lv YH, Zheng DY, Xia ZF et al. (2010). Metabolomic analysis of thermally injured and/or septic rats. Burns 36: 992-998.
87. Liu Y, Wu H, Nie Y-C, Chen J-L, Su W-W, Li P-B (2011b). Naringin attenuates acute lung injury in LPS-treated mice by inhibiting NF-κB pathway. Int Immunopharmacol 11: 1606-1612.
88. Lopez A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S et al. (2004). Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 32: 21-30.
89. Ma P, Liu H-T, Wei P, Xu Q-S, Bai X-F, Du Y-G et al. (2011). Chitosan oligosaccharides inhibit LPS-induced over-expression of IL-6 and TNF-α in RAW264.7 macrophage cells through blockade of mitogen-activated protein kinase (MAPK) and PI3K/Akt signaling pathways. Carbohydr Poly 84: 1391-1398.
90. Madrigal-Carballo S, Rodríguez G, Sibaja M, Reed JD, Vila AO, Molina F (2009). Chitosomes loaded with cranberry proanthocyanidins attenuate the bacterial lipopolysaccharide-induced expression of iNOS and COX-2 in raw 264.7 macrophages. J Liposome Res 19: 189-196.
91. Marik PE, Raghavan M (2004). Stress-hyperglycemia, insulin and immunomodulation in sepsis. Intensive Care Med 30: 748-756.
92. Marshall JC (2014). Why have clinical trials in sepsis failed? Trends Mol Med 20: 195-203.
93. Martire-Greco D, Landoni VI, Chiarella P, Rodriguez-Rodrigues N, Schierloh P, Rearte B et al. (2014). all-trans-Retinoic acid improves immunocompetence in a murine model of lipopolysaccharide-induced immunosuppression. Clin Sci (Lond) 126: 355-365.
94. Matthay MA (2001). Severe sepsis - a new treatment with both anticoagulant and antiinflammatory properties. N Engl J Med 344: 759-762.
95. Matthay MA, Ware LB (2004). Can nicotine treat sepsis? Nat Med 10: 1161-1162.
96. Mattsby-Baltzer I, Roseanu A, Motas C, Elverfors J, Engberg I, Hanson LA (1996). Lactoferrin or a fragment thereof inhibits the endotoxin-induced interleukin-6 response in human monocytic cells. Pediatr Res 40: 257-262.
97. Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J et al. (2009). Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression. Am J Respir Crit Care Med 180: 640-648.
98. Melamed A, Sorvillo FJ (2009). The burden of sepsis-associated mortality in the United States from 1999 to 2005: an analysis of multiple-cause-of-death data. Crit Care 13: R28.
99. Mishra PR (2011). An investigation on the approach to target lipopolysaccharide through polymeric capped nano-structured formulation for the management of sepsis. J Biomed Nanotechnol 7: 47-49.
100. Muenzer JT, Davis CG, Chang K, Schmidt RE, Dunne WM, Coopersmith CM et al. (2010). Characterization and modulation of the immunosuppressive phase of sepsis. Infect Immun 78: 1582-1592.
101. Mullarkey M, Rose JR, Bristol J, Kawata T, Kimura A, Kobayashi S et al. (2003). Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther 304: 1093-1102.
102. Novelli G, Morabito V, Ferretti G, Novelli S, Ruberto F, Pernice M et al. (2012). Polymixin-B hemoperfusion in a case intolerant to conventional antibiotic therapy. Journal of Biomed Sci Eng 5: 101-103.
103. Opal SM, Patrozou E (2009). Translational research in the development of novel sepsis therapeutics: logical deductive reasoning or mission impossible? Crit Care Med 37: S10-S15.
104. Opal SM, Laterre P, Francois B, La Rosa SP, Angus DC, Mira J et al. (2013). Effect of eritoran, an antagonist of md2-tlr4, on mortality in patients with severe sepsis: the access randomized trial. JAMA 309: 1154-1162.
105. Park K (2013). Facing the truth about nanotechnology in drug delivery. ACS Nano 7: 7442-7447.
106. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, Davenport AP, McGrath JC, Peters JA, Southan C, Spedding M, Yu W, Harmar AJ; NC-IUPHAR. (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-1106.
107. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R (2007). Nanocarriers as an emerging platform for cancer therapy. Nat Nano 2: 751-760.
108. Pereira V, Serpa Neto A, Cardoso S, Manetta J, Esposito D, de Oliveira Prado Pasqualucci M et al. (2013). Association between use of lung-protective ventilation with lower tidal volumes and risk of acute lung injury, mortality, pulmonary infection, and atelectasis: a meta-analysis. Critical care 17 (Suppl. 3): P38.
109. van der Poll T, Opal SM (2008). Host-pathogen interactions in sepsis. Lancet Infect Dis 8: 32-43.
110. Ponnappa BC, Dey I, Tu G-C, Zhou F, Aini M, Cao Q-N et al. (2001). In vivo delivery of antisense oligonucleotides in pH-sensitive liposomes inhibits lipopolysaccharide-induced production of tumor necrosis factor-α in rats. J Pharmacol Exp Ther 297: 1129-1136.
111. Puddu P, Latorre D, Valenti P, Gessani S (2010). Immunoregulatory role of lactoferrin-lipopolysaccharide interactions. Biometals 23: 387-397.
112. Qiao Y, Bai XF, Du YG (2011). Chitosan oligosaccharides protect mice from LPS challenge by attenuation of inflammation and oxidative stress. Int Immunopharmacol 11: 121-127.
113. Radnai B, Tucsek Z, Bognar Z, Antus C, Mark L, Berente Z et al. (2009). Ferulaldehyde, a water-soluble degradation product of polyphenols, inhibits the lipopolysaccharide-induced inflammatory response in mice. J Nutr 139: 291-297.
114. von Ranke FM, Zanetti G, Hochhegger B, Marchiori E (2013). Infectious diseases causing diffuse alveolar hemorrhage in immunocompetent patients: a state-of-the-art review. Lung 191: 9-18.
115. Rearte B, Maglioco A, Balboa L, Bruzzo J, Landoni VI, Laborde EA et al. (2010). Mifepristone (RU486) restores humoral and T cell-mediated immune response in endotoxin immunosuppressed mice. Clin Exp Immunol 162: 568-577.
116. Rearte B, Maglioco A, Machuca D, Greco DM, Landoni VI, Rodriguez-Rodrigues N et al. (2013). Dehydroepiandrosterone and metyrapone partially restore the adaptive humoral and cellular immune response in endotoxin immunosuppressed mice. Innate Immunity 20: 585-597.
117. Remick DG (2007). Pathophysiology of sepsis. Am J Pathol 170: 1435-1444.
118. Riedemann NC, Guo R-F, Ward PA (2003). The enigma of sepsis. J Clin Invest 112: 460-467.
119. Riedemann NC, Guo RF, Gao H, Sun L, Hoesel M, Hollmann TJ et al. (2004). Regulatory role of C5a on macrophage migration inhibitory factor release from neutrophils. J Immunol 173: 1355-1359.
120. Rittirsch D, Flierl MA, Ward PA (2008). Harmful molecular mechanisms in sepsis. Nat Rev Immunol 8: 776-787.
121. Salvesen GS, Riedl SJ (2008). Caspase mechanisms. Adv Exp Med Biol 615: 13-23.
122. Sha T, Sunamoto M, Kitazaki T, Sato J, Ii M, Iizawa Y (2007). Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model. Eur J Pharmacol 571: 231-239.
123. Shai Y, Makovitzky A, Avrahami D (2006). Host defense peptides and lipopeptides: modes of action and potential candidates for the treatment of bacterial and fungal infections. Curr Protein Peptide Sci 7: 479-486.
124. Shao B, Munford RS, Kitchens R, Varley AW (2012). Hepatic uptake and deacylation of the LPS in bloodborne LPS-lipoprotein complexes. Innate Immun 18: 825-833.
125. Shukla P, Srivastava AK (2012). Different fabrication processes and polymer blends for sustained release matrix tablets of highly water soluble drug (metoprolol succinate): an in vitro evaluation. Inventi Impact: Pharm Tech. Available at: http://www.inventi.in/Article/ppt/463/12.aspx (accessed 9/3/2014).
126. Shukla P, Gupta G, Singodia D, Shukla R, Verma AK, Dwivedi P et al. (2010). Emerging trend in nano-engineered polyelectrolytebased surrogate carriers for delivery of bioactives. Expert Opin Drug Deliv 7: 993-1011.
127. Singh AK, Jiang Y, Gupta S, Younus M, Ramzan M (2013). Anti-inflammatory potency of nano-formulated puerarin and curcumin in rats subjected to the lipopolysaccharide-induced inflammation. J Med Food 16: 899-911.
128. Singodia D, Kansal S, Verma A, Shukla R, Shukla P, Dwivedi P et al. (2010). Development of nevirapine loaded novel surfactant free polymeric emulsion and investigations for its suitability as drug delivery vehicle. J Bionanosci 4: 66-73.
129. Song Y, Dou H, Gong W, Liu X, Yu Z, Li E et al. (2013). Bis-N-norgliovictin, a small-molecule compound from marine fungus, inhibits LPS-induced inflammation in macrophages and improves survival in sepsis. Eur J Pharmacol 705: 49-60.
130. Stefan M, Melnig V, Pricop D, Neagu A, Mihasan M, Tartau L et al. (2013). Attenuated effects of chitosan-capped gold nanoparticles on LPS-induced toxicity in laboratory rats. Mater Sci Eng 33: 550-556.
131. Strachan AJ, Woodruff TM, Haaima G, Fairlie DP, Taylor SM (2000). A new small molecule C5a receptor antagonist inhibits the reverse-passive Arthus reaction and endotoxic shock in rats. J Immunol 164: 6560-6565.
132. Stringer KA, Serkova NJ, Karnovsky A, Guire K, Paine R 3rd, Standiford TJ (2011). Metabolic consequences of sepsis-induced acute lung injury revealed by plasma (1)H-nuclear magnetic resonance quantitative metabolomics and computational analysis. Am J Physiol Lung Cell Mol Physiol 300: L4-L11.
133. Sun D, Zhuang X, Xiang X, Liu Y, Zhang S, Liu C et al. (2010). A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Molecular Therapy 18: 1606-1614.
134. Suntres ZE, Shek PN (2000). Prophylaxis against lipopolysaccharide-induced lung injuries by liposome-entrapped dexamethasone in rats. Biochem Pharmacol 59: 1155-1161.
135. Tang D, Kang R, Xiao W, Zhang H, Lotze MT, Wang H et al. (2009). Quercetin prevents LPS-induced high-mobility group box 1 release and proinflammatory function. Am J Respir Cell Mol Biol 41: 651-660.
136. Tang Y, Lv B, Wang H, Xiao X, Zuo X (2008). PACAP inhibit the release and cytokine activity of HMGB1 and improve the survival during lethal endotoxemia. Int Immunopharmacol 8: 1646-1651.
137. The Lancet Infectious Diseases (2012). For sepsis, the drugs don't work. Lancet Infect Dis 12: 89.
138. Thierry Calandra BE, Le Roy D, Pugin J, Metz CN, Hültner L, Heumann D et al. (2001). Protection from septic shock by neutralization of macrophage migration inhibitory factor. Pediatr Infect Dis J 20: 470-471.
139. Tohyama S, Onodera S, Tohyama H, Yasuda K, Nishihira J, Mizue Y et al. (2008). A novel DNA vaccine-targeting macrophage migration inhibitory factor improves the survival of mice with sepsis. Gene Ther 15: 1513-1522.
140. Toussaint S, Gerlach H (2009). Activated protein C for sepsis. N Engl J Med 361: 2646-2652.
141. Tse MT (2013). Trial watch: sepsis study failure highlights need for trial design rethink. Nat Rev Drug Discov 12: 334-334.
142. Tsoyi K, Jang HJ, Kim JW, Chang HK, Lee YS, Pae HO et al. (2011). Stimulation of alpha7 nicotinic acetylcholine receptor by nicotine attenuates inflammatory response in macrophages and improves survival in experimental model of sepsis through heme oxygenase-1 induction. Antioxid Redox Signal 14: 2057-2070.
143. Ulloa L, Ochani M, Yang H, Tanovic M, Halperin D, Yang R et al. (2002). Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci U S A 99: 12351-12356.
144. Urban C, Zychlinsky A (2007). Netting bacteria in sepsis. Nat Med 13: 403-404.
145. Vallespi MG, Alvarez-Obregon JC, Rodriguez-Alonso I, Montero T, Garay H, Reyes O et al. (2003). A Limulus anti-LPS factor-derived peptide modulates cytokine gene expression and promotes resolution of bacterial acute infection in mice. Int Immunopharmacol 3: 247-256.
146. Veronese FM, Caliceti P, Schiavon O, Sergi M (2002). Polyethylene glycol-superoxide dismutase, a conjugate in search of exploitation. Adv Drug Deliv Rev 54: 587-606.
147. Vicent MJ, Cascales L, Carbajo RJ, Cortes N, Messeguer A, Perez Paya E (2010). Nanoconjugates as intracorporeal neutralizers of bacterial endotoxins. J Control Release 142: 277-285.
148. Wang W, Luo M, Fu Y, Wang S, Efferth T, Zu Y (2013). Glycyrrhizic acid nanoparticles inhibit LPS-induced inflammatory mediators in 264.7 mouse macrophages compared with unprocessed glycyrrhizic acid. Int J Nanomedicine 8: 1377-1383.
149. Wannemuehler TJ, Manukyan MC, Brewster BD, Rouch J, Poynter JA, Wang Y et al. (2012). Advances in mesenchymal stem cell research in sepsis. J Surg Res 173: 113-126.
150. Warren HS, Suffredini AF, Eichacker PQ, Munford RS (2002). Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med 347: 1027-1030.
151. Weber P, Wang P, Maddens S, Wang P, Wu R, Miksa M et al. (2009). VX-166: a novel potent small molecule caspase inhibitor as a potential therapy for sepsis. Critical Care 13: R146.
152. Wu J, Zhou L, Liu J, Ma G, Kou Q, He Z et al. (2013). The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Critical Care 17: R8.
153. Yang M, Cao L, Xie M, Yu Y, Kang R, Yang L et al. (2013). Chloroquine inhibits HMGB1 inflammatory signaling and protects mice from lethal sepsis. Biochem Pharmacol 86: 410-418.
154. Yang R, Gallo DJ, Baust JJ, Uchiyama T, Watkins SK, Delude RL et al. (2002). Ethyl pyruvate modulates inflammatory gene expression in mice subjected to hemorrhagic shock. Am J Physiol Gastrointest Liver Physiol 283: G212-G221.
155. Yang SC, Bhide M, Crispe IN, Pierce RH, Murthy N (2008). Polyketal copolymers: a new acid-sensitive delivery vehicle for treating acute inflammatory diseases. Bioconjug Chem 19: 1164-1169.
156. Yermak IM, Davidova VN, Gorbach VI, Luk'yanov PA, Solov'eva TF, Ulmer AJ et al. (2006). Forming and immunological properties of some lipopolysaccharide-chitosan complexes. Biochimie 88: 23-30.
157. Yibin G, Jiang Z, Hong Z, Gengfa L, Liangxi W, Guo W et al. (2005). A synthesized cationic tetradecapeptide from hornet venom kills bacteria and neutralizes lipopolysaccharide in vivo and in vitro. Biochem Pharmacol 70: 209-219.
158. Yin JP, Su ZL, Wang YM, Wang T, Tian SS, Xu XX et al. (2012). Release of HMGB1 by LPS-treated cardiac fibroblasts and its contribution to the production of collagen type I and III]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 28: 785-788.
159. Yuan Z, Syed MA, Panchal D, Rogers D, Joo M, Sadikot RT (2012). Curcumin mediated epigenetic modulation inhibits TREM-1 expression in response to lipopolysaccharide. Int J Biochem Cell Biol 44: 2032-2043.
160. Zaborin A, Defazio JR, Kade M, Kaiser BLD, Belogortseva N, Camp DG et al. (2014). Phosphate-containing polyethylene glycol polymers prevent lethal sepsis from multidrug-resistant pathogens. Antimicrob Agents Chemother 58: 966-977.
161. Zheng X, Yang D, Liu X, Wang N, Li B, Cao H et al. (2010). Identification of a new anti-LPS agent, geniposide, from Gardenia jasminoides Ellis, and its ability of direct binding and neutralization of lipopolysaccharide in vitro and in vivo. Int Immunopharmacol 10: 1209-1219.